854
Views
12
CrossRef citations to date
0
Altmetric
Research Article

The Effect of Shark Cartilage Extracts on the Growth and Metastatic Spread of the SCCVII Carcinoma

, &
Pages 441-445 | Published online: 08 Jul 2009

References

  • Mathews J. Media feeds frenzy over shark cartilage as cancer treatment. J Natl Cancer Inst 1993; 85: 1190–1.
  • Mathews J. Sharks still intrigue cancer researchers. J Natl Cancer Inst 1992; 84: 1000–2.
  • Lane IW, Comac L. Sharks don't get cancer. New York: Avery, 1993.
  • Markman M. Shark cartilage: the Laetrile of the 1990s. Cleve Clin J Med 1996; 63: 179–80.
  • Blood CH, Zetter BR. Tumor interactions with the vascula-ture: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89–118.
  • Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
  • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27–31.
  • Folkman J. The vascularization of tumors. Sci Am 1976; 234: 58–73.
  • Paweletz N, Knierim M. Tumor-related angiogenesis. Crit Rev Oncol Hematol 1989; 9: 197–242.
  • Mahadevan V, Hart IR. Metastasis and angiogenesis. Rev Oncol 1990; 3: 97–103.
  • Brem H, Folkman J. Inhibition of tumor angiogenesis medi-ated by cartilage. J Exp Med 1975; 141: 427–39.
  • Langer R, Brem H, Falterman K, Klein M, Folkman J. Isolation of a cartilage factor that inhibits tumor neovascular-ization. Science 1976; 193: 70–2.
  • Langer R, Conn H, Vacanti J, Haudenschild C, Folkman J. Control of tumor growth in animals by infusion of an angio-genesis inhibitor. Proc Natl Acad Sci USA 1980; 77: 4331–5.
  • Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248: 1408–10.
  • Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983; 221: 1185–7.
  • McGuire TR, Kazakoff PW, Hoie EB, Feinhold MA. An-tiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothe-1Mm. Pharmacotherapy 1996; 16: 237–44.
  • Hirst DG, Brown JM, Hazelhurst JL. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br J Cancer 1982; 46: 109–16.
  • Hirst DG, Horsman MR, Brown JM, Hazelhurst J. The effect of timing on chemosensitization by clinical levels of SR-2508. Int J Radiat Oncol Biol Phys 1984; 10: 1641–5.
  • Horsman MR, Wood PJ, Chaplin DJ, Brown JM, Overgaard J. The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother Oncol 1990; 18: 49–57.
  • Grau C, Nordsmark M, Khalil AA, Horsman MR, Over-gaard J. Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo. Int J Radiat Oncol Biol Phys 1994; 29: 449–54.
  • Wood PJ, Horsman MR, Khalil AA, et al. A comparison of the physiological effects of RSU 1069 and RB 6145 in the SCCVII murine tumour. Acta Oncol 1996; 35: 989–94.
  • Nishimura Y, Murata R, Hiraoka M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996; 73: 270–4.
  • Ramsey J, Suit HD, Sedlacek R. Experimental studies on the incidence of metastases after failure of radiation treatment and the effect of salvage surgery. Int J Radiat Oncol Biol Phys 1988; 14: 1165–8.
  • Ogawa Y, Goodman GB, Chaplin DJ, Grulkey W, Lam GK. Combination therapy of pions and SPG (Sonifilan, Schizo-phyllan), a biological response modifier for mouse tumor systems. Int J Radiat Oncol Biol Phys 1990; 18: 1415–20.
  • Miller DR, Granick JL, Stark JJ, Anderson GT. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancers. ASCO Proceedings 1997; 16: 49a.
  • DeVita VT. Principles of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and prac-tice of oncology, 3rd ed. Philadelphia: JB Lippincott, 1989: 276–300.
  • O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 1994; 79: 315–28.
  • Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts hu-man plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996; 56: 4887–990.
  • Good DL, Polverini PJ, Rastinejad F, et al. A tumor suppres-sor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of throm-bospondin. Proc Natl Acad Sci USA 1990; 87: 6624–8.
  • O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an en-dogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.
  • Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangio-genic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.